Fundraising Fox

Gur Roshwalb

Investor

Executive at Akari Therapeutics

Ra'anana, Israel

Writes $100K – $5M checks · typically $1.5M

Find your path to Gur

528 people in our graph share verified history with Gur — schools, employers, funds. One of them is your warm intro.

Tom DanilekunlockedGur: together at Columbia University (1987–1989)
×4Gur: together at Columbia University
×4Gur: together at Piper Jaffray
Gur: together at NYU Stern School of Business

About

Gur Roshwalb is CEO of 1E Therapeutics and Board Observer at CPTx. He has experience spanning clinical medicine, sell-side research, buy-side investing, and clinical development, with a track record of building and managing private and public life science companies from startup through Phase II development.

Executive at Akari Therapeutics

Intro paths

→

In turn, Gur can intro founders to Akari Therapeutics's investors below.

Akari Therapeutics's investors · 1

New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks

Experience

  1. CPTxBoard Observercurrent2024 — presentGermany
  2. 1E TherapeuticsChief Executive Officercurrent2024 — presentRehovot, Center District, Israel
  3. KAHR-medical Ltd.Board Member2021 — 2024
  4. Biosplice TherapeuticsBoard Member2021 — 2024United States
  5. AltruBio Inc.Board Member2020 — 2024
  6. MiNA TherapeuticsBoard Member2020 — 2024United Kingdom
  7. aMoon FundPartner2019 — 2024Israel
  8. Viracta Therapeutics, Inc.Board Member2020 — 2022
  9. Zywie Bio LLCCEO2017 — 2018
  10. GeNO, LLCConsultant2017
  11. Akari Therapeutics PlcCEO2015 — 2017New York/London
  12. Celsus Therapeutics, PlcCEO2013 — 2015Greater New York City Area
  13. Venrock AssociatesVice President2008 — 2013
  14. Piper JaffrayBiotech Analyst2004 — 2008
  15. Manhattan Internal Medicine AssociatesInternist, Partner1998 — 2004
  16. Mount Sinai Medical CenterChief Resident1997 — 1998

Skills & more

Non-Executive Director9Board Level7Early Stage Investment7Start-up VenturesDrug DevelopmentPortfolio strategyFinancial Modeling32Informatics3Venture Capital32Private Equity10Due Diligence10Investments7
+10 moreCorporate DevelopmentValuationEquity ResearchMergers & AcquisitionsBiotechnologyInvestor RelationsIpoIPOAnalysisCMC

Languages Hebrew

From Gur's professional profile.

Deals · 1

Viracta TherapeuticsBoard seat

via aMoon · filed Dec 2020 · $40M raise

Attribution from SEC filings, press coverage, and firm rosters.

Network1

Avital Adler
Principal at Arkin Capital

Investors connected to Gur in public investor directories — a warm-intro map.

Frequently asked questions

Who is Gur Roshwalb?
Gur Roshwalb is CEO of 1E Therapeutics and Board Observer at CPTx. He has experience spanning clinical medicine, sell-side research, buy-side investing, and clinical development, with a track record of building and managing private and public life science companies from startup through Phase II development.
Where does Gur Roshwalb work?
Gur Roshwalb is Executive at Akari Therapeutics.
What check size does Gur Roshwalb write?
Gur Roshwalb typically writes checks of $100K – $5M.
What boards does Gur Roshwalb sit on?
Gur Roshwalb holds tracked board seats at Viracta Therapeutics.
Where did Gur Roshwalb go to school?
Gur Roshwalb studied at NYU Stern School of Business (MBA, Finance); Icahn School of Medicine at Mount Sinai (Residency, Internal Medicine Residency Program); Albert Einstein College of Medicine (MD, Medicine).

Same school

Also attended NYU Stern School of Business820

Luna SchmidInvestor at GV (Google Ventures)Kaz TeradaVenture Advisor at Monta Vista CapitalNeil FongManaging Director Asia at Burda Principal InvestmentsMax WechterSenior Director of AI at Lerer HippeauKrupa VankayalaPartner, People & HR at Sapphire VenturesDanny BrowneInvestor at FJ Labs

+ 814 more

Also attended Icahn School of Medicine at Mount Sinai37

Justin RobenyAssociate at Osage University PartnersOmar Njie, MDPrincipal at AlleyCorpVinod MittaVenture Partner at Floating PointTara BishopInvestor at Black Opal VenturesScott GottliebPartner at New Enterprise Associates (NEA)Sharon HuangAssociate at Tau Ventures

+ 31 more

Also attended Albert Einstein College of Medicine21

Perry NisenExecutive Advisor, Private Equity at Sofinnova VenturesRichard StumacherClinical Advisor at Seae VenturesScott BraunsteinVice-Chairman of the Board and Director at atai Life SciencesSam GoldbergerManaging Partner at Ambit Health VenturesDr. Yair SapersteinFounder / CEO at AvoSaurabh GombarCo-Founder & Chief Medical Officer at Atropos Health

+ 15 more

Also attended Columbia University1,302

Ben HorowitzCo-founder & General Partner at Andreessen HorowitzDoug LeonePartner at Sequoia Capital; former Global Managing PartnerChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzKai-Fu LeeChairman of Sinovation Ventures and CEO of 01.AIGabriella GiglioHR & Executive Talent at General CatalystScott BillerInvestor at GV (Google Ventures)

+ 1,296 more

Shared employers

Also worked at KAHR-medical Ltd.1

Michel HabibCo-Founder, Managing General Partner at ALIVE Israel HealthTech Fund

Also worked at AltruBio Inc.3

Tomer BerkovitzManaging Partner at aMoonAvital AdlerPrincipal at Arkin CapitalPatrick Y. YangCo-founder, former EVP of Juno Therapeutics, Roche and Genentech at Acepodia

Also worked at MiNA Therapeutics2

Albert KwokFounder at Nuntius TherapeuticsRobert HabibChief Executive Officer at Minatx

Also worked at aMoon Fund22

Yair SchindelCo-Founder & Managing Partner at aMoonOsnat TiroshChief People Officer & Chief of Staff at aMoonTomer BerkovitzManaging Partner at aMoonTodd SoneGeneral Partner at aMoonMoshic MorGeneral Partner at aMoonYaron DanielyGeneral Partner & Head of aMoon Alpha at aMoon

+ 16 more